Streetbeat News

Regulatory

ADIL

Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been granted a US patent (number 11957664) for a combination of its proprietary genetic diagnostic and its lead investigational drug, AD04, for treating alcohol use disorder (AUD) and other drug dependencies such as opioid use disorder (OUD). This patent strengthens Adial's intellectual property portfolio, covering specific genotypes for targeted treatment. The addressable market for these treatments in the U.S. is estimated at $40 billion. Additionally, Adial has previously received a patent for AD04 targeting the serotonin transporter gene for potential OUD treatment and published positive clinical results and safety profiles for AD04.

Portfolio Pulse from Vandana Singh

April 22, 2024 | 12:00 pm

ADIL

Adial Therapeutics has been granted a key patent from the United States Patent and Trademark Office, according to an exclusive report by Benzinga. This development could potentially enhance the company's intellectual property portfolio and strengthen its position in its respective market.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:00 pm

JNJ

The European Commission (EC) has approved Carvykti for the treatment of relapsed or refractory multiple myeloma, according to Bloomberg. This approval marks a significant milestone for patients with this condition, offering a new therapeutic option. Johnson & Johnson (JNJ), likely involved in the development or distribution of Carvykti, may see a positive impact from this news.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:57 am

MLEC

Moolec Science shares surged following the announcement of USDA approval for its plant-grown animal proteins, marking a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:42 am

KURA

Kura Oncology's stock price increased following the FDA's Breakthrough Therapy Designation for Ziftomenib, aimed at treating NPM1-Mutant AML.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:39 am

LXEO

Lexeo Therapeutics has entered into an in-license agreement with Cornell University to accelerate the development of LX2006 for treating Friedreich Ataxia Cardiomyopathy. This agreement grants Lexeo certain rights, including access to current and future data from an ongoing Phase 1A trial of AAVrh.10hFXN aimed at treating FA cardiomyopathy.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:32 am

KURA

Kura Oncology's drug, Ziftomenib, received FDA Breakthrough Therapy Designation for treating relapsed/refractory NPM1-mutant Acute Myeloid Leukemia, potentially accelerating its development and review process.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:32 am

CNTA

The FDA has approved Centessa Pharmaceuticals' application to begin a Phase 1 clinical trial of ORX750, a new drug aimed at treating narcolepsy. This marks a significant step for Centessa in advancing its pipeline and potentially addressing a critical need in narcolepsy treatment.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:09 am

MRNA

Moderna has secured a contract with Brazil's Ministry of Health to supply 12.5 million doses of its mRNA COVID-19 vaccine, scheduled for delivery in Q2 2024. This follows the Brazilian Health Regulatory Agency's approval of Moderna's updated COVID-19 vaccine in March 2024.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:06 am

PSTV

Plus Therapeutics Inc (NASDAQ:PSTV) is set to receive a $3 million funding recommendation from the Department of Defense for expanding its pediatric brain cancer clinical trial. The funding, expected to start in Q3 2024, will support the trial's expansion and extend the company's cash runway into the second half of 2025. Plus Therapeutics is focusing on a novel therapeutic, Rhenium (186Re) Obisbemeda, for treating pediatric high-grade glioma and ependymoma, with patient enrollment anticipated in the second half of 2024.

Portfolio Pulse from Vandana Singh

April 22, 2024 | 11:00 am